REMARKS

The Official Action dated September 14, 2006 has been carefully considered. It is believed that the present Amendment places the application in condition for allowance. Reconsideration is respectfully requested.

By the present amendment, various claims are amended to more clearly define the invention. Claim 47 is added and is directed to a selected embodiment of previous claim 35. It is believed that these changes do not involve any introduction of new matter, whereby entry is believed to be in order and is respectfully requested.

Claims 34, 35 and 44 were rejected under 35 U.S.C. §112, first paragraph, as not being enabled by the present specification. The Examiner asserted that while the specification is enabling for a vaccine against Timothy grass Phl p2 pollen allergen specific human IgE Fab as defined in claim 45, it does not provide enablement for a vaccine against any grass pollen allergy comprising the IgE Fab. With respect to claim 35, the Examiner asserted that "passive immunotherapy" includes both preventive and therapeutic purposes but the present specification only discloses prevention (i.e., by vaccine) with respect to Timothy Grass Phl p2 allergen.

This rejection is traversed. However, to expedite prosecution, claims 34 and 44 now recite vaccines against Timothy grass pollen allergy as exemplified in the specification. It should be noted that the vaccine is against the Timothy grass pollen, as described at page 3, lines 14-15 of the specification, not the Phl p2 molecule per se. Additionally, claim 35 now recites passive immunotherapy of Timothy Grass pollen allergy. Applicants therefore submit that these claims are enabled by the present specification in accordance with the requirements of 35 U.S.C. §112, first paragraph, whereby the rejection of claims 34, 35 and 44 has been overcome. Reconsideration is respectfully requested.

Claims 25-29, 32-34, 39-40 and 42 and 44 were rejected under 35 U.S.C. §112, first paragraph, on the basis that they contain subject matter which was not described in the specification in such a way as to convey to one skilled in the art that the inventors had possession of the claimed invention at the time of the application. With respect to claims 25 and 39, the Examiner asserted that the specification does not provide a written description of any combination of the recited heavy chains and light chains. Second, the Examiner objected to the recitation of "human IgG" in claims 26-29 and 40 on the basis that the present specification only exemplifies IgG1. Third, the Examiner questioned the meaning of "the corresponding complete antibody" in claims 32 and 42, and claims 33 and 43 dependent thereon.

This rejection is traversed. With respect to claims 25 and 29, the present specification clearly discloses the similarities of the recited heavy chains, for example at pages 8-10 and in the Figures. Additionally, the IgE Fabs recited in claims 25 and 29 each contain only nine possible combinations of the heavy chains and light chains. Further, the Examiner's attention is directed to the specification at page 15, beginning at line 13:

> It has been demonstrated that the Phl p 5-specific IgE heavy chain fragments can be recombined with light chains from antibodies with different specificity but retain antigen-specificity (15, Laffer and Valenta, unpublished data). Also our study indicates that similar heavy chain fragments can recombine with different light chains but retain specificity for the original allergen.

Accordingly, the present specification clearly describes the subject matter of claims 25 and 39 wherein any of the three heavy chains can be combined with any of the three light chains while retaining antigen specificity and therefore provides a written description of all of the IgE Fabs of claims 25 and 39.

Further, claims 26-29 and 40 now recite IgG1 as exemplified in the specification, and the reference to the complete antibody is omitted from claims 32 and 42. Applicants therefore submit that claims 25-29, 32-34, 39-40 and 42 and 44 are described in the present

specification in accordance with the requirements of 35 U.S.C. §112, first paragraph, whereby the rejection of these claims has been overcome. Reconsideration is respectfully requested.

Finally, in the Official Action, claims 26 and 40 were rejected under 35 U.S.C. §112, first paragraph, on the basis that the recitation of human IgG, rather than human IgG1, introduces new matter into the application. This rejection is traversed. However, as noted above, claims 26-29 and 40 now recite IgG1 as exemplified in the specification. Applicants therefore submit that claims 26-29 and 40 are described in the present specification in accordance with the requirements of 35 U.S.C. §112, first paragraph, whereby the rejection of these claims has been overcome. Reconsideration is respectfully requested.

It is believed that the above represents a complete response to the rejections under 35 U.S.C. §112, first paragraph, set forth in the Official Action, and places the present application in condition for allowance. Reconsideration and an early allowance are requested.

Respectfully submitted,



Holly D. Kozlowski, Reg. No. 30,468
DINSMORE & SHOHL LLP
1900 Chemed Center
255 E. Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

1333063v1